Home > Dermatology > EADV 2020 > Late-Breaking News > Selective IL-23 blocker shows potential in psoriasis treatment

Selective IL-23 blocker shows potential in psoriasis treatment

Presented By
Dr Kim Papp, Probity Medical Research, Canada
Conference
EADV 2020
Trial
Phase 3, OASIS-2
The IL-23p19 class antibody mirikizumab demonstrated superiority to placebo and non-inferiority to secukinumab in the treatment of psoriasis up to 52 weeks. “Mirikizumab is a humanised, IgG4-variant monoclonal antibody binding to p19, thereby blocking IL-23,” explained Dr Kim Papp (Probity Medical Research, Canada). He reported on the primary and major secondary efficacy and safety outcomes of mirikizumab versus secukinumab and placebo in the treatment of psoriasis at week 52 [1]. The phase 3, randomised, multicentre OASIS-2 study (NCT03535194) included over 1,400 adult patients with moderate-to-severe plaque psoriasis. The study consisted of an induction period to week 16 and a blinded maintenance period lasting to week 52. Patients were initially randomised 4:4:4:1 to receive either 250 mg mirikizumab every 4 weeks in 2 arms, or secukinumab or placebo ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on